


Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

UTSD:553/WIM

Serial No.

09/339,352

Applicant

Berenice Y. Reed-Gitomer and Charles Y.C. Pak

Filing Date:

June 23, 1999

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>HAR</i>	A1	4,683,202	07/28/87	Mullis	435	91	10/25/85

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>HAR</i>	C1	Abbondanzo <i>et al.</i> , "Prognostic significance of immunocytochemically determined ps2 in axillary node-negative breast carcinoma," <i>Breast Cancer Res. Treat.</i> , 16:182 (#151), 1990.
<i>HAR</i>	C2	Abrams, "Clinical studies of mineral metabolism in children using stable isotopes," <i>J. Ped. Gastroenter. Nutr.</i> , 19:151-163, 1994.
<i>HAR</i>	C3	Allred <i>et al.</i> , "Comprehensive evaluation of prognostic factors by immunocytochemistry on extremely small samples (50 MG) of "pulverized" breast carcinomas," <i>Breast Cancer Res. Treat.</i> , 16:182 (#149), 1990.
<i>HAR</i>	C4	Bataille <i>et al.</i> , "Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone-formers," <i>Kidney Intern.</i> , 39:1193-1205, 1991.
<i>HAR</i>	C5	Breslau <i>et al.</i> , "Use of ketoconazole to probe the pathogenic importance of 1,25-dihydroxyvitamin D in absorptive hypercalciuria," <i>J. Clin. Endocrinol Metab.</i> , 75:1446-1452, 1992.
<i>HAR</i>	C6	Brown <i>et al.</i> , "Prognostic significance and clinical-pathological correlations of cell-cycle kinetics measured by KI-7 immunocytochemistry in axillary node-negative carcinoma of the breast," <i>Breast Cancer Res. Treat.</i> , 16:192 (#191), 1990.
<i>HAR</i>	C7	Buck <i>et al.</i> , "Cytosolic adenylyl cyclase defines a unique signalling molecule in mammals," <i>Proc. Natl. Acad. Sci. USA</i> , 96: 79-84
<i>HAR</i>	C8	Collins <i>et al.</i> , "A metric map of humans: 23,500 loci in 850 bands," <i>Proc. Natl. Acad. Sci. USA</i> , 93:14771-14775, 1996.

EXAMINER:

Hope Robinson


DATE CONSIDERED:

3/30/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)



Atty. Docket No.

PTSD:553/WIM

Serial No.

09/339,352

List of Patents and Publications for Applicant's Training

Applicant

Berenice Y. Reed-Gitomer and Charles Y.C. Pak

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 23, 1999

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>HR</i>	C9	DeMay <i>et al.</i> , "Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D ₃ receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D ₃ ," <i>Proc. Natl. Acad. Sci.</i> , 89: 8097-8101, 1992.
<i>HR</i>	C10	Fujita and Swaroop, "Alu-Vector PCR with Biotinylated Primers to Isolate YAC Ends Ready for Sequencing," <i>BioTechniques</i> 18: 796-799, 1995.
<i>HR</i>	C11	Heller <i>et al.</i> , "Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria," <i>J. Urol.</i> , 159:1451-1456, 1988.
<i>HR</i>	C12	Hess <i>et al.</i> , "Relative Hypoparathyroidism and Calcitriol Up-Regulation in Hypercalciuric Calcium Renal Stone Formers - Impact of Nutrition," <i>Am. J. Nephrol.</i> 13:18-26, 1993.
<i>HR</i>	C13	Horrigan and Westbrook, "Construction and Use of YAC Contigs in Disease Regions," <i>Gene Isolation and Mapping Protocols</i> , Human Press, ed. J. Boultonwood, 123-125, 1997.
<i>HR</i>	C14	Krieger <i>et al.</i> , "Increased sensitivity to 1,25(OH) ₂ D ₃ in bone from genetic hypercalciuric rats," <i>J. Physiol.</i> 271:C130-C135, 1996.
<i>HR</i>	C15	Krizman, "Gene Isolation by Exon Trapping," <i>Gene Isolation and Mapping Protocols</i> , Human Press, ed. J. Boultonwood, 167-182, 1997.
<i>HR</i>	C16	Kruglyak <i>et al.</i> , "Parametric and non-parametric linkage analysis: a unified multilocus approach," <i>Am. J. Hum. Genet.</i> , 58:1347-1363, 1996.
<i>HR</i>	C17	Lathrop <i>et al.</i> , "Multilocus Linkage Analysis in Humans: Detection Linkage and Estimation of Recombination," <i>Am. J. Hum. Genet</i> 37:482-498, 1985.
<i>HR</i>	C18	Ledbetter <i>et al.</i> , "Rapid Isolation of DNA Probes within Specific Chromosome Regions by Interspersed Repetitive Sequence Polymerase Chain Reaction," <i>Genomics</i> 6: 475-481, 1990.
<i>HR</i>	C19	Levy <i>et al.</i> , "Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol," <i>Am. J. Med.</i> , 98:50-59, 1995.
<i>HR</i>	C20	Li <i>et al.</i> , "Increased intestinal vitamin D receptor in genetic hypercalciuric rats: a cause of intestinal calcium hyperabsorption," <i>J. Clin. Invest.</i> , 91:661-667, 1993.
<i>HR</i>	C21	Lloyd <i>et al.</i> , "A common molecular basis for three inherited kidney stone diseases," <i>Nature</i> , 379:445-449, 1996.

EXAMINER:

Ape Robinson

DATE CONSIDERED:

8/30/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

MAR 13 2000

Atty. Docket No.
UTSD:553/WIMSerial No.
09/339,352

List of Patents and Publications for Applicant's

Applicant

Berenice Y. Reed-Gitomer and Charles Y.C. Pak

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
June 23, 1999Group:
1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Pacifici <i>et al.</i> , "Increased Monocyte Interleukin-1 Activity and Decreased Vertebral Bone Density in Patients with Fasting Idiopathic Hypercalciuria," <i>J. Clin. Endo. Metab.</i> , 71:138-145, 1990.
	C23	Pak and Galosy, "Fasting urinary calcium and adenosine 3', 5'-monophosphate: a discriminant analysis for the identification of renal and absorptive hypercalciurias," <i>J. Clin. Endocrinol. Metab.</i> , 48: 260-265, 1979.
	C24	Pak <i>et al.</i> , "A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias," <i>N. Engl. J. Med.</i> , 292:497-500, 1975.
	C25	Pak <i>et al.</i> , "Ambulatory evaluation of nephrolithiasis: classification clinical presentation, and diagnostic criteria," <i>Am. J. Med.</i> , 69:19-30, 1980.
	C26	Pak <i>et al.</i> , "Familial absorptive hypercalciuria in a large kindred," <i>J. Urology</i> , 126:717-719, 1981.
	C27	Pak <i>et al.</i> , "The hypercalciurias: causes, parathyroid functions and diagnostic criteria," <i>J. Clin. Invest.</i> , 54:387-400, 1974.
	C28	Pietchmann <i>et al.</i> , "Reduced vertebral bone density in hypercalciuric nephrolithiasis," <i>J. Bone Min. Res.</i> , 7:1383-1388, 1992.
	C29	Preminger <i>et al.</i> , "Differentiation of unclassified hypercalciuria utilizing a sodium cellulose phosphate trial," <i>In Urolithiasis</i> , Walker, Sutton, Cameron, Pak, Robertson (eds.), Plenum Press New York and London, 325-328, 1989.
	C30	Reed <i>et al.</i> , "Linkage analysis in absorptive hypercalciuria: lack of linkage to the vitamin D receptor or 1,25(OH) ₂ D ₃ hydroxylase loci," <i>In Urolithiasis</i> , Pak, Resnick, Preminger (eds.), Millet Press, Dallas, TX, 540-542, 1996.
	C31	Reed <i>et al.</i> , "Mapping a Gene Defect in Absorptive Hypercalciuria to Chromosome 1q23.3-q24*," <i>Journal of Clinical Endocrinology & Metabolism</i> 84:3907 - 3913, 1999.
	C32	Ruml <i>et al.</i> , "Medical Therapy; Calcium Oxalate Urolithiasis," <i>Urol. Clinics of N. Am.</i> 24:117-132, 1997.
	C33	Tenenhouse, "Cellular and molecular mechanisms of renal phosphate transport," <i>J. Bone Min. Res.</i> , 12:159-163, 1997.

EXAMINER:


DATE CONSIDERED:

2/30/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)



Atty. Docket No.

UTSD:553/WIM

Serial No.

09/339,352

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Berenice Y. Reed-Gitomer and Charles Y.C. Pak

Filing Date:

June 23, 1999

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>ARC</i>	C34	Weisinger <i>et al.</i> , "Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria," <i>Kidney Int.</i> 49:244-250, 1996.
<i>HAC</i>	C35	Zerwekh <i>et al.</i> , "Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in absorptive hypercalciuria," <i>J. Clin. Endocrinol. Metab.</i> , 80:2960-2965, 1995.
<i>HAC</i>	C36	Zerwekh <i>et al.</i> , "Vitamin D receptor quantitation in human mononuclear cells in health and disease," <i>Mol. Cell Endocrinol.</i> , 96:1-6, 1993.
<i>HAC</i>	C37	Imamura <i>et al.</i> , "4q33-qter deletion and absorptive hypercalciuria: report of two unrelated girls," <i>American J. of Med. Gene.</i> , 78:52-54, 1998.
<i>HAC</i>	C38	Lemann, Jr. and Gray, "Idiopathic hypercalciuria," <i>J. of Urology</i> , 141:715-718, 1989.
<i>HAC</i>	C39	Pearce <i>et al.</i> , "A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor," <i>The New England J of Med.</i> , 335:1115-1122, 1996.
<i>HAC</i>	C40	Thakker, "Renal chloride channel, CLCN%, mutations and hypercalciuric nephrolithiasis disorders," <i>Nova Acta Leopoldina NF</i> , 302:23-33, 1997.

EXAMINER:

Hope Robinson

DATE CONSIDERED:

3/30/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)